Traditional Chinese Medicine company Regencell Bioscience listed on the NASDAQ in July 2021. The company was attacked by short-seller Peabody Street Research in March 2022 alleging a number of corporate governance issues such as professional misconduct and questionable use of funds. The company's CFO resigned a month later although its share price has held up well. Additional clarity might be provided when the company published its next audited financials for end-June FY22, due to be published in October.

Last updated August 2022.

The information on this page has been compiled from publicly available sources. GMT Research Limited has not verified the information and does not warrant its accuracy. Any claims made or views expressed are not necessarily those of GMT Research Limited.